Table of Contents Table of Contents
Previous Page  48 / 164 Next Page
Information
Show Menu
Previous Page 48 / 164 Next Page
Page Background

48

ESTRO SCHOOL

TARGET GROUP

The course is primarily aimed at trainees in radiation

oncology, supportive care personnel, radiation ther-

apists (RTTs) and at radiation oncologists early in

their career and/or eager to update their knowledge of

general and organ specific morbidity aspects inmodern

radio-(chemo-/targeted-) therapy. For PhD students

in radiation oncology and related disciplines, this

course can broaden their knowledge. As the focus is on

clinical applications, the competences of the teachers’

team comprise radiation oncology, gastroenterology,

psychology and radiobiology.

COURSE AIM

For the lectures, the aims are to:

• Introduce general principles of normal tissue radio-

pathogenesis and radiobiology

• Provide approaches for assessment and documentation

of treatment-related morbidity

• Provide management strategies for “systemic” mor-

bidity (nausea/emesis, fatigue)

• Illustrate important facets of treatment-/morbidity-re-

lated quality of life (including assessment instruments)

and emotional dysfunction

• Provide a comprehensive overview over relevant and

currently accepted approaches for prevention, mitiga-

tion and treatment of adverse events and supportive

care

• Detail specific aspects of morbidity in abdominal

and pelvic radiation oncology (gastrointestinal tract

including. liver and pancreas, urinary tract including

kidney, sexual organs and function).

Complimentary to the lectures, general discussion

sessions and clinical case presentations will serve to

illustrate the relevance of the various aspects of mor-

bidity for daily clinical work, and to answer specific

(morbidity-related) questions.

LEARNINGOUTCOMES

By the end of this course participants should be able to:

• Understand the underlying (radio)biology of treat-

ment-related morbidity

• Identify, classify and document treatment-related

morbidity in cancer survivors

• Identify the impact of treatment-related morbidity

on patients’ quality of life

• Provide strategies for management of systemic

morbidity

• Provide strategies for prevention of treatment-related

morbidity

• Provide supportive care and organ-specific morbidity

management to cancer survivors.

COURSE CONTENT

1. General lectures on:

• The relevance of treatment-related morbidity for

cancer survivors

• General pathogenesis of normal tissue reactions

• Classification and documentation of morbidity

• Reporting: prevalence vs. incidence

• Impact of exposure parameters (4 R’s of radiotherapy)

• Volume effects and tolerance concepts

• General morbidity: fatigue, nausea and emesis

• Quality of life: general aspects, documentation

• Psychological disorders/emotional dysfunction

• Coping with disease and post-disease life

• Management and supportive care guidelines

• Specific aspects of chemo-/immunotherapy.

2. Module-specific lectures on:

• Skin and adnexae

• Spinal cord, peripheral nerves

• Gastrointestinal tract

• Liver and pancreas

• Urinary tract, including kidneys

• Sexual organs and function

• Aspects of paediatric (radio-)oncology.

3. Clinical case discussions:

The participants are invited to collectively discuss

expected (based on treatment protocol and planning)

morbidity and to develop management strategies of

observed adverse events in clinical cases prepared by

the faculty and/or put forward by participants.

Cancer Survivorship

21-23 May 2017

Brussels, Belgium